BRPI0615145A2 - derivados de xantina como agonistas hm74a seletivos - Google Patents
derivados de xantina como agonistas hm74a seletivosInfo
- Publication number
- BRPI0615145A2 BRPI0615145A2 BRPI0615145-0A BRPI0615145A BRPI0615145A2 BR PI0615145 A2 BRPI0615145 A2 BR PI0615145A2 BR PI0615145 A BRPI0615145 A BR PI0615145A BR PI0615145 A2 BRPI0615145 A2 BR PI0615145A2
- Authority
- BR
- Brazil
- Prior art keywords
- derivatives
- xanthine derivatives
- selective
- hm74a agonists
- compounds
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 abstract 2
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0516464A GB0516464D0 (en) | 2005-08-10 | 2005-08-10 | Novel compounds |
| GB0607736A GB0607736D0 (en) | 2006-04-19 | 2006-04-19 | Novel compounds |
| GB0614569A GB0614569D0 (en) | 2006-07-21 | 2006-07-21 | Novel compounds |
| PCT/EP2006/007869 WO2007017262A1 (en) | 2005-08-10 | 2006-08-08 | Xanthine derivatives as selective hm74a agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0615145A2 true BRPI0615145A2 (pt) | 2009-11-03 |
Family
ID=37189397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0615145-0A BRPI0615145A2 (pt) | 2005-08-10 | 2006-08-08 | derivados de xantina como agonistas hm74a seletivos |
| BRPI0614270-2A BRPI0614270A2 (pt) | 2005-08-10 | 2006-08-08 | derivados xantina como seletivos agonistas de ha74a |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0614270-2A BRPI0614270A2 (pt) | 2005-08-10 | 2006-08-08 | derivados xantina como seletivos agonistas de ha74a |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20100179128A1 (OSRAM) |
| EP (3) | EP2272848B1 (OSRAM) |
| JP (2) | JP5112316B2 (OSRAM) |
| KR (2) | KR20080038396A (OSRAM) |
| AR (1) | AR055369A1 (OSRAM) |
| AT (1) | ATE487719T1 (OSRAM) |
| AU (2) | AU2006278216A1 (OSRAM) |
| BR (2) | BRPI0615145A2 (OSRAM) |
| CA (2) | CA2626723A1 (OSRAM) |
| CR (2) | CR9748A (OSRAM) |
| CY (1) | CY1111757T1 (OSRAM) |
| DE (1) | DE602006018151D1 (OSRAM) |
| DK (1) | DK1912991T3 (OSRAM) |
| EA (2) | EA014556B1 (OSRAM) |
| ES (1) | ES2401128T3 (OSRAM) |
| HR (1) | HRP20100725T1 (OSRAM) |
| IL (2) | IL189081A0 (OSRAM) |
| MA (2) | MA29693B1 (OSRAM) |
| MX (2) | MX2008001929A (OSRAM) |
| MY (1) | MY142067A (OSRAM) |
| NO (2) | NO20081211L (OSRAM) |
| NZ (1) | NZ565494A (OSRAM) |
| PE (1) | PE20070405A1 (OSRAM) |
| PL (1) | PL1912991T3 (OSRAM) |
| PT (1) | PT1912991E (OSRAM) |
| SI (1) | SI1912991T1 (OSRAM) |
| TW (1) | TW200800217A (OSRAM) |
| WO (2) | WO2007017262A1 (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
| PT1781657E (pt) * | 2004-02-14 | 2013-05-23 | Glaxosmithkline Ip Dev Ltd | Medicamentos com actividade no receptor hm74a |
| DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
| WO2007017262A1 (en) * | 2005-08-10 | 2007-02-15 | Smithkline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
| AU2007260852B2 (en) | 2006-06-23 | 2013-01-10 | Incyte Corporation | Purinone derivatives as HM74a agonists |
| CA2656039A1 (en) | 2006-06-23 | 2007-12-27 | Incyte Corporation | Purinone derivatives as hm74a agonists |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| JP5666464B2 (ja) | 2008-12-08 | 2015-02-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 新規化合物 |
| ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR101799429B1 (ko) | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| CA2807364A1 (en) * | 2010-08-16 | 2012-02-23 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| US8580825B2 (en) * | 2010-09-23 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EA201492069A1 (ru) * | 2012-05-30 | 2015-03-31 | Ф.Хоффманн-Ля Рош Аг | Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10) |
| KR102227629B1 (ko) * | 2013-03-15 | 2021-03-16 | 하이드라 바이오사이언시스, 엘엘씨 | 치환된 잔틴 및 그것의 사용 방법 |
| JP6434498B2 (ja) | 2013-05-10 | 2018-12-05 | ギリアド アポロ， エルエルシー | Ａｃｃ阻害剤及びその使用 |
| HK1221420A1 (zh) | 2013-05-10 | 2017-06-02 | Gilead Apollo, Inc. | Acc抑制剂和其用途 |
| KR20160005364A (ko) | 2013-05-10 | 2016-01-14 | 님버스 아폴로, 인코포레이티드 | Acc 억제제 및 이의 용도 |
| MX2015015417A (es) * | 2013-05-10 | 2016-06-21 | Nimbus Apollo Inc | Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos. |
| CN105646492B (zh) * | 2014-11-14 | 2019-04-09 | 中国医学科学院药物研究所 | 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途 |
| DE102017000359A1 (de) | 2016-08-26 | 2018-03-01 | Bihl+Wiedemann Gmbh | Diagnose-Repeater für AS-Interface Netze |
| CN110461838B (zh) * | 2017-03-07 | 2022-05-06 | 豪夫迈·罗氏有限公司 | 噁二唑瞬时受体电位通道抑制剂 |
| CN112724141A (zh) * | 2021-01-21 | 2021-04-30 | 南京艾美斐生物医药科技有限公司 | 一种gpr109a蛋白受体抑制剂及其制备和应用 |
| CR20240352A (es) * | 2022-02-03 | 2024-09-18 | De Shaw Res Llc | Compuestos de uracilo sustituidos por n3 como inhibidores de trpa1 |
| EP4658262A1 (en) * | 2023-01-30 | 2025-12-10 | D.E. Shaw Research, LLC | Bicyclic imide compounds as trpa1 inhibitors |
| AR133217A1 (es) * | 2023-07-10 | 2025-09-10 | De Shaw Res Llc | Inhibidores de trpa1 bicíclicos y monocíclicos |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2797220A (en) | 1954-12-02 | 1957-06-25 | Univ Michigan | Substituted paraxanthines |
| GB8906792D0 (en) | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| IL100088A (en) | 1990-11-21 | 1995-07-31 | Smithkline Beecham Corp | FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8 |
| AU3725893A (en) | 1992-02-21 | 1993-09-13 | Smithkline Beecham Corporation | TNF inhibitors |
| DE69332634T2 (de) | 1992-03-04 | 2003-05-08 | Cell Therapeutics, Inc. | Enantiomere hydroxylierte xanthinverbindungen |
| US5473070A (en) | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
| US5780476A (en) | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
| US6469017B1 (en) | 1998-01-16 | 2002-10-22 | Cell Therapeutics, Inc. | Method of inhibiting interleukin-12 signaling |
| US6693105B1 (en) | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| IL109161A0 (en) | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
| US5670506A (en) | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
| AU6702894A (en) | 1993-04-09 | 1994-11-08 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| AU1868195A (en) | 1994-01-28 | 1995-08-15 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6780865B1 (en) | 1994-02-18 | 2004-08-24 | Cell Therapeutics, Inc. | Compounds having selective hydrolytic potentials |
| AU1967495A (en) | 1994-02-18 | 1995-09-04 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
| US6103730A (en) | 1994-03-24 | 2000-08-15 | Cell Therapeutics, Inc. | Amine substituted compounds |
| US6878715B1 (en) | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
| US5807861A (en) | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
| US6323201B1 (en) * | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| AR015966A1 (es) | 1997-10-17 | 2001-05-30 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito |
| MXPA01010143A (es) | 1999-04-09 | 2003-07-14 | Cell Therapeutics Inc | Derivados de xantina y analogos como inhibidores de transmision de senales celulares. |
| US20030207901A1 (en) | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
| US6586429B2 (en) * | 2000-11-29 | 2003-07-01 | Cell Therapeutics, Inc. | Tricyclic fused xanthine compounds and their uses |
| CZ305402B6 (cs) | 2001-02-24 | 2015-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthinové deriváty, jejich výroba a použití v kombinační terapii |
| AU2002242910A1 (en) | 2001-04-11 | 2002-10-28 | Glaxo Group Limited | Medicaments which are modulators of hm74 and/or hm74a activity |
| ATE388951T1 (de) * | 2001-07-03 | 2008-03-15 | Novo Nordisk As | Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes |
| EP1338595B1 (en) | 2002-02-25 | 2006-05-03 | Eisai Co., Ltd. | Xanthine derivatives as DPP-IV inhibitors |
| US7482337B2 (en) | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
| CN1227492C (zh) * | 2003-03-11 | 2005-11-16 | 张跃 | 一种吸收式空调主体 |
| GB0319124D0 (en) * | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| PT1781657E (pt) | 2004-02-14 | 2013-05-23 | Glaxosmithkline Ip Dev Ltd | Medicamentos com actividade no receptor hm74a |
| WO2006045564A1 (en) * | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with hm74a receptor activity |
| AU2005298891A1 (en) * | 2004-10-22 | 2006-05-04 | Smithkline Beecham Corporation | Xanthine derivatives with HM74A receptor activity |
| US20090209561A1 (en) * | 2004-10-22 | 2009-08-20 | Richard Jonathan Daniel Hatley | Xanthine Derivatives with HM74A Receptor Activity |
| US20080221108A1 (en) | 2005-02-14 | 2008-09-11 | Richard Hatley | Anthranilic Acid Derivatives As Hm74A Receptor Agonists |
| GB0516462D0 (en) * | 2005-08-10 | 2005-09-14 | Smithkline Beecham Corp | Novel compounds |
| WO2007017262A1 (en) * | 2005-08-10 | 2007-02-15 | Smithkline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
| DE102008009758A1 (de) * | 2008-02-18 | 2009-08-20 | Beiersdorf Ag | Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite |
| JP5666464B2 (ja) | 2008-12-08 | 2015-02-12 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 新規化合物 |
-
2006
- 2006-08-08 WO PCT/EP2006/007869 patent/WO2007017262A1/en not_active Ceased
- 2006-08-08 US US12/063,432 patent/US20100179128A1/en not_active Abandoned
- 2006-08-08 PE PE2006000963A patent/PE20070405A1/es not_active Application Discontinuation
- 2006-08-08 AR ARP060103459A patent/AR055369A1/es unknown
- 2006-08-08 MX MX2008001929A patent/MX2008001929A/es not_active Application Discontinuation
- 2006-08-08 WO PCT/EP2006/007865 patent/WO2007017261A1/en not_active Ceased
- 2006-08-08 MX MX2008001931A patent/MX2008001931A/es active IP Right Grant
- 2006-08-08 CA CA002626723A patent/CA2626723A1/en not_active Abandoned
- 2006-08-08 CA CA002618963A patent/CA2618963A1/en not_active Abandoned
- 2006-08-08 AU AU2006278216A patent/AU2006278216A1/en not_active Abandoned
- 2006-08-08 NZ NZ565494A patent/NZ565494A/en not_active IP Right Cessation
- 2006-08-08 TW TW095128952A patent/TW200800217A/zh unknown
- 2006-08-08 US US12/063,434 patent/US8143264B2/en not_active Expired - Fee Related
- 2006-08-08 EA EA200800555A patent/EA014556B1/ru not_active IP Right Cessation
- 2006-08-08 BR BRPI0615145-0A patent/BRPI0615145A2/pt not_active Application Discontinuation
- 2006-08-08 EP EP10172674A patent/EP2272848B1/en active Active
- 2006-08-08 EP EP06776699A patent/EP1912992A1/en not_active Withdrawn
- 2006-08-08 AU AU2006278215A patent/AU2006278215A1/en not_active Abandoned
- 2006-08-08 BR BRPI0614270-2A patent/BRPI0614270A2/pt not_active IP Right Cessation
- 2006-08-08 SI SI200630916T patent/SI1912991T1/sl unknown
- 2006-08-08 AT AT06763016T patent/ATE487719T1/de active
- 2006-08-08 HR HR20100725T patent/HRP20100725T1/hr unknown
- 2006-08-08 EP EP06763016A patent/EP1912991B1/en active Active
- 2006-08-08 JP JP2008525474A patent/JP5112316B2/ja not_active Expired - Fee Related
- 2006-08-08 KR KR1020087005724A patent/KR20080038396A/ko not_active Withdrawn
- 2006-08-08 JP JP2008525475A patent/JP2009504592A/ja not_active Withdrawn
- 2006-08-08 KR KR1020087005717A patent/KR20080034993A/ko not_active Ceased
- 2006-08-08 DK DK06763016.0T patent/DK1912991T3/da active
- 2006-08-08 DE DE602006018151T patent/DE602006018151D1/de active Active
- 2006-08-08 ES ES10172674T patent/ES2401128T3/es active Active
- 2006-08-08 PT PT06763016T patent/PT1912991E/pt unknown
- 2006-08-08 EA EA200800564A patent/EA200800564A1/ru unknown
- 2006-08-08 PL PL06763016T patent/PL1912991T3/pl unknown
- 2006-08-08 MY MYPI20063833A patent/MY142067A/en unknown
-
2008
- 2008-01-28 IL IL189081A patent/IL189081A0/en unknown
- 2008-01-28 IL IL189083A patent/IL189083A0/en unknown
- 2008-02-08 MA MA30629A patent/MA29693B1/fr unknown
- 2008-02-08 MA MA30628A patent/MA29692B1/fr unknown
- 2008-02-21 CR CR9748A patent/CR9748A/es not_active Application Discontinuation
- 2008-02-21 CR CR9749A patent/CR9749A/es not_active Application Discontinuation
- 2008-03-07 NO NO20081211A patent/NO20081211L/no not_active Application Discontinuation
- 2008-03-07 NO NO20081212A patent/NO20081212L/no not_active Application Discontinuation
-
2011
- 2011-01-12 CY CY20111100033T patent/CY1111757T1/el unknown
- 2011-04-18 US US13/088,962 patent/US20110257205A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0615145A2 (pt) | derivados de xantina como agonistas hm74a seletivos | |
| BRPI0517458A (pt) | derivados da xantina com atividade para o receptor hm74a | |
| BRPI0618552B8 (pt) | compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos | |
| HRP20130406T1 (hr) | Medikamenti s aktivnošä†u prema receptoru hm74a | |
| BRPI0512796A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf, e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença | |
| BRPI0416801A (pt) | derivados de 1h-imidazoquinolina como inibidores de proteìna sinase | |
| BR112012016330B8 (pt) | ativadores de tieno [2, 3-b] piridinadiona de ampk e composição farmacêutica compreendendo os mesmos | |
| BRPI0717156B8 (pt) | inibidores do co-transportador 2 da glicose de sódio e composição farmacêutica que os compreende | |
| BRPI0713443A2 (pt) | Derivados de piperazinila úteis no tratamento de doenças medianas por receptor gpr38, uso e composição farmacêutica contendo tais compostos e processos para preparação dos mesmos | |
| BRPI0805826B8 (pt) | compostos espiro-substituídos, composição farmacêutica e uso | |
| BRPI0613570A8 (pt) | composto ou um sal do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto. | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| UA104988C2 (uk) | Похідні піроніндолу та спосіб їх отримання | |
| BRPI0514310A (pt) | 8-aminoalcóxi-xantinas substituìdas, método para a produção das mesmas e seu uso como medicamentos | |
| UY29092A1 (es) | Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| BRPI0607583A2 (pt) | derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos | |
| BRPI0513744A (pt) | derivados de guanidina e usos terapêuticos dos mesmos | |
| ECSP088472A (es) | Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento | |
| DE502007002949D1 (de) | Proteinbindende methotrexat-derivate und diese enthaltende arzneimittel | |
| BRPI0908569B8 (pt) | estimuladores de secreção de insulina derivados de piridopirazinonas, seu uso, e composição farmacêutica | |
| MX2008001211A (es) | Derivados de bencilpiperazina y su uso medico. | |
| DOP2006000024A (es) | Tiazolidinonas, su preparación y su uso como medicamento | |
| AR048672A1 (es) | Tabletas de desintegracion que comprenden licarbazepina | |
| UA95780C2 (en) | Xanthine derivatives as selective hm74a agonists | |
| BRPI0714672B8 (pt) | derivados de camptotecina, composição farmacêutica contendo os mesmos e seu uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |